NICE rejects eribulin for breast cancer

The National Institute for Health and Clinical Excellence (NICE) has decided that eribulin (Halaven) should not be made available on the NHS.

Eribulin is not recommended for the treatment of breast cancer on the NHS | SCIENCE PHOTO LIBRARY
Eribulin is not recommended for the treatment of breast cancer on the NHS | SCIENCE PHOTO LIBRARY

The outcome was based on the side-effect profile of eribulin in comparison to other established available treatments.

Halaven is licensed for use as monotherapy in treating patients with locally advanced or metastatic breast cancer which has progressed after at minimum of two chemotherapeutic regimens.

Further information

NICE guidance on eribulin for breast cancer

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more